drugset
Drugs / mRNA-1345
last change Jul 2026 re-read 2 minutes ago

mRNA-1345

also known as mRESVIA

Messenger RNA (mRNA)

Developed for
respiratory syncytial virus infectious disease
Investigated by
ModernaTX, Inc.

Trials 12 · a red edge is where a trial was stopped

today NCT07117487 · Ph 3 NCT06143046 · Ph 2 NCT06097299 · Ph 2 NCT06067230 · Ph 3 NCT06060457 · Ph 3 NCT05743881 · Ph 1 NCT05606965 · Ph 2 NCT05585632 · Ph 1 NCT05397223 · Ph 1 NCT05330975 · Ph 3 NCT05127434 · Ph 2/3 NCT04528719 · Ph 1
202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT05743881 Feb 2023 → Aug 2029 expected respiratory syncytial virus infectious disease ModernaTX, Inc. Active not recruiting No outcome recorded
Phase 1 NCT05585632 Oct 2022 → Feb 2024 Orthocoronavirinae infectious disease, influenza, respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 1 NCT05397223 May 2022 → Feb 2026 COVID-19, cytomegalovirus infection, influenza, respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 1 NCT04528719 Sep 2020 → Jul 2024 respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT06143046 Nov 2023 → May 2026 respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 2 NCT06097299 Oct 2023 → Jun 2025 respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 2 NCT05606965 Nov 2022 → Nov 2025 influenza ModernaTX, Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05127434 Nov 2021 → Jul 2025 respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 34 trials
Phase 3 NCT07117487 Aug 2025 → Mar 2026 respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 3 NCT06067230 Oct 2023 → Jul 2026 overdue respiratory syncytial virus infectious disease ModernaTX, Inc. Active not recruiting No outcome recorded
Phase 3 NCT06060457 Sep 2023 → Jun 2024 respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded
Phase 3 NCT05330975 Apr 2022 → Nov 2024 respiratory syncytial virus infectious disease ModernaTX, Inc. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2024-02-08 ModernaTX, Inc. Statement on RSVVW Abstract on mRNA-1345 modernatx.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as mRNA-1345 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07117487 ↗
11

NCT06097299 ↗

NCT05606965 ↗

NCT05127434 ↗

NCT05330975 ↗

NCT04528719 ↗

NCT05397223 ↗

NCT06060457 ↗

NCT06067230 ↗

NCT05585632 ↗

NCT06143046 ↗

NCT05743881 ↗
Known as mRESVIA “mRNA-1345 (mRESVIA, Moderna, Inc.) is indicated in multiple countries for prevention of RSV-lower respiratory tract disease in adults.” PMID 42048601 ↗ Apr 2026
Modality Messenger RNA (mRNA) “A lipid nanoparticle-encapsulated mRNA-based RSV vaccine (mRNA-1345) that encodes the membrane-anchored RSV prefusion-stabilized F glycoprotein” PMID 38298125 ↗ Sep 2024
Route Intramuscular “Single injection of mRNA-1345 administered IM on BD Day 1.” NCT05330975 ↗